Toxicogenomics in biomarker discovery

Methods in Molecular Biology

Volumn 460, Issue , 2008, Pages 185-194

  Decristofaro, Marc F ^a   Daniels, Kellye K ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Gene Logic   (United States)

Author keywords

Biomarker; Blood; Gene expression; Heart; Kidney; Molecular profiling; Toxicogenomics; Transcriptomics

Indexed keywords

EID: 84934443476     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60327-48-9_9     Document Type: Article

References (43)

1. International Human Genome Sequencing Consortium. (2001) Nature 409, 860-921.
2. Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., et al. (2001) Science 291, 1304-1351.
3. Biomarkers Definitions Working Group. (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95.
4. Bailey, W.J. and Ulrich, R. (2004) Molecular profiling approaches for identifying novel biomarkers. Expert Opin. Drug Saf. 3, 137-151.
5. Guerreiro, N., Staedtler, F., Grenet, O., Kehren, J., and Chibout, S.D. (2003) Toxicogenomics in drug development. Toxicol. Pathol. 31, 471-479.
6. Feng, Z., Prentice, R., and Srivastava, S. (2004) Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics 5, 709-719.
7. Negm, R.S., Verma, M., and Srivastava, S. (2002) The promise of biomarkers in cancer screening and detection. Trends Mol. Med. 8, 288-293.
8. Goodsaid, F.M. (2004) Identification and measurement of genomic biomarkers of nephrotoxicity. J. Pharmacol. Toxicol. Methods 49, 183-186.
9. Perazella, M.A. (2003) Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am. J. Med. Sci. 325, 349-362.
10. Templin, M.V., Jamison, K.C., Wolf, D.C., Morgan, K.T., and Butterworth, B.E. (1996) Comparison of chloroform-induced toxicity in the kidneys, liver, and nasal passages of male Osborne-Mendel and F-344 rats. Cancer Lett. 104, 71-78.
11. Stacchiotti, A., Borsani, E., Rodella, L., Rezzani, R., Bianchi, R., and Lavazza, A. (2003) Dose-dependent mercuric chloride tubular injury in rat kidney. Ultrastruct. Pathol. 27, 253-259.
12. Stacchiotti, A., Lavazza, A., Rezzani, R., Borsani, E., Rodella, L., and Bianchi, R. (2004) Mercuric chloride-induced alterations in stress protein distribution in rat kidney. Histol. Histopathol. 19, 1209-1218.
13. Kramer, J.A., Pettit, S.D., Amin, R.P., Bertram, T.A., Car, B., Cunningham, M., et al. (2004) Overview on the application of transcription profiling using selected nephrotoxicants for toxicology assessment. Environ. Health Perspect. 112, 460-464.
14. Fernandez-Tome, M.C., and Sterin-Speziale, N.B. (1994) Short- and long-term treatment with indomethacin causes renal phospholipid alteration: a possible explanation for indomethacin nephrotoxicity. Pharmacology 48, 341-348.
15. Han, W.K., Bailly, V., Abichandani, R., Thadhani, R., and Bonventre, J.V. (2002) Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 62, 237-244.
16. Hewitt, S.M., Dear, J., and Star, R.A. (2004) Discovery of protein biomarkers for renal diseases. J. Am. Soc. Nephrol. 15, 1677-1689.
17. Rosenberg, M.E. and Silkensen, J. (1995) Clusterin: physiologic and pathophysiologic considerations. Int. J. Biochem. Cell. Biol. 27, 633-645.
18. Drew, A.F., Tucker, H.L., Liu, H., Witte, D.P., Degen, J.L., and Tipping, P.G. (2001) Crescentic glomerulonephritis is diminished in fibrinogen-deficient mice. Am. J. Physiol. Renal Physiol. 281, F1157-1163.
19. Amin, R.P., Vickers, A.E., Sistare, F., Thompson, K.L., Roman, R.J., Lawton, M., et al. (2004) Identification of putative gene based markers of renal toxicity. Environ. Health Perspect. 112, 465-479.
20. Chevalier, R.L. (2004) Biomarkers of congenital obstructive nephropathy: past, present and future. J. Urol. 172, 852-857.
21. Grenet, O., Varela, M.C., Staedtler, F., and Steiner, S. (1998) The cyclosporine A-induced decrease in rat renal calbindin-D28kDa protein as a consequence of a decrease in its mRNA. Biochem. Pharmacol. 55, 1131-1133.
22. Krischer, J.P., Epstein, S., Cuthbertson, D.D., Goorin, A.M., Epstein, M.L., and Lipshultz, S.E. (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer. the pediatric oncology group experience. J. Clin. Oncol. 15, 1544-1552.
23. Keefe, D.L. (2002) Trastuzumab-associated cardiotoxicity. Cancer 95, 1592-1600.
24. Kruit, W.H., Punt, K.J., Goey, S.H., de Mulder, P.H., van Hoogenhuyze, D.C., Henzen-Logmans, S.C., and Stoter, G. (1994) Cardiotoxicity as a doselimiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication. Cancer 74, 2850-2856.
25. Alert for Healthcare Professionals Valdecoxib (marketed as Bextra). http://www.fda.gov/cder/drug/InfoSheets/HCP/valdecoxibHCP.htm.
26. Recanatini, M., Poluzzi, E., Masetti, M., Cavalli, A., and De Ponti, F. (2005) QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. Med. Res. Rev. 25, 133-166.
27. Wallace, K.B., Hausner, E., Herman, E., Holt, G.D., MacGregor, J.T., Metz, A.L., et al. (2004) Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol. Pathol. 32, 106-121.
28. Marian, A.J. and Nambi, V. (2004) Biomarkers of cardiac disease. Expert Rev. Mol. Diagn. 4, 805-820.
29. Kang, Y.J. (2001) Molecular and cellular mechanisms of cardiotoxicity. Environ. Health Perspect. 109 (Suppl 1), 27-34.
30. Schwartz, L., Boheler, K.R., De La Bastie, D., Lompre, A.M., and Mercadier, J-J. (1992) Switches in cardiac muscle gene expresion as a result of pressure and volume overload. Am. J. Physiol. 262, R364-369.
31. Rozich, J.D., Barnes, M.A., Schmid, P.G., Zile, M.R., McDermott, P.J., and Cooper, G. (1995) Load effects on gene expression during cardiac hypertrophy. J. Mol. Cell. Cardiol. 27, 485-499.
32. Chien, K.R., Knowlton, K.U., Zhu, H., and Chien, S. (1991) Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J. 5, 3037-3046.
33. Kolbeck-Ruhmkorff, C. and Zimmer, H.G. (1995) Proto-oncogene expression in the isolated working rat heart: combination of pressure and volume overload with norepinephrine. J. Mol. Cell. Cardiol. 27, 501-511.
34. Lee, W.M. (2003) Drug-induced hepatotoxicity. N. Engl. J. Med. 349, 474-485.
35. Park, B.K., Kitteringham, N.R., Maggs, J.L., Pirmohamed, M., and Williams, D.P. (2005) The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45, 177-202.
36. Kew, M.C. (2000) Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet 355, 591-592.
37. Kaplan, M.M. (2002) Alanine aminotransferase levels: what's normal? Ann. Intern. Med. 137, 49-51.
38. Bauer, I., Rensing, H., Florax, A., Ulrich, C., Pistorius, G., Redl, H., and Bauer, M. (2003) Expression pattern and regulation of heme oxygenase-1/heat shock protein 32 in human liver cells. Shock 20, 116-122.
39. Fang, C.W., Yao, Y.M., Shi, Z.G., Yu, Y., Wu, Y., Lu, L.R., and Sheng, Z.Y. (2002) Lipopolysaccharide-binding protein and lipopolysaccharide receptor CD14 gene expression after thermal injury and its potential mechanism(s). J. Trauma 53, 957-967.
40. Flo, T.H., Smith, K.D., Sato, S., Rodriguez, D.J., Holmes, M.A., Strong, R.K., et al. (2004) Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432, 917-921.
41. Petricoin, E.F., Zoon, K.C., Kohn, E.C., Barrett, J.C., and Liotta, L.A. (2002) Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 1, 683-695.
42. Fan, H. and Hegde, P.S. (2005) The transcriptome in blood: challenges and solutions for robust expression profiling. Curr. Mol. Med. 5, 3-10.
43. ® Expression Profiling Santa Clara, CA.